Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

Rhea-AI Summary

Prelude Therapeutics announced its participation in three healthcare investment conferences in February 2023. On February 14, CEO Kris Vaddi and CMO Jane Huang will engage in a fireside chat at the SVB Securities Global Biopharma Conference, followed by one-on-one investor meetings. On February 21, executives will participate in the 2023 Wells Fargo Targeted Protein Degradation Summit, with talks focusing on key protein degradation targets in oncology. Prelude is a clinical-stage oncology company with a pipeline of innovative drug candidates, including PRT1419 and PRT3879, aimed at addressing critical cancer pathways.

WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February.

• On Tuesday, February 14, at 8:40 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference. The live webcast is available here. They will be joined by Laurent Chardonnet, Chief Financial Officer, for one-on-one meetings with investors during the conference.
  
  
• On Tuesday, February 21, two executives will speak at the 2023 Wells Fargo Targeted Protein Degradation Summit, taking place virtually.
  
  
  • Peggy Scherle, Ph.D., Chief Scientific Officer will join the 12:00 p.m. ET panel, “Key Targets for Targeted Protein Degradation in Oncology and Potential Combination Strategies.”
    
    
  • Andrew Combs, Ph.D., Executive Vice President and Head of Chemistry, will speak at 1:00 p.m. ET on the panel entitled, “Degradation vs. Inhibition – When does Targeted Protein Degradation make Sense and When Does it Not?”

About Prelude

Prelude is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Prelude’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a brain penetrant CDK4/6 inhibitor, and PRT3879 a first-in-class SMARCA2/BRM protein degrader.

For more information, visit our website and follow us on LinkedIn and Twitter.

Investor Contact:
Lindsey Trickett
Vice President, Investor Relations
240.543.7970
ltrickett@preludetx.com

Media Contact:
Helen Shik
Shik Communications
617.510.4373
Helen@ShikCommunications.com

FAQ

What events will Prelude Therapeutics participate in during February 2023?

Prelude Therapeutics will participate in three healthcare investment conferences in February 2023, including the SVB Securities Global Biopharma Conference on February 14 and the Wells Fargo Targeted Protein Degradation Summit on February 21.

Who are the key executives speaking at the SVB Securities Global Biopharma Conference?

At the SVB Securities Global Biopharma Conference, the key executives speaking are Kris Vaddi, CEO, and Jane Huang, CMO, alongside CFO Laurent Chardonnet.

What topics will be discussed at the Wells Fargo Targeted Protein Degradation Summit?

At the Wells Fargo Targeted Protein Degradation Summit, discussions will include key targets for drug degradation in oncology and comparison of degradation versus inhibition strategies.

What are the main drug candidates in Prelude's pipeline?

Prelude's pipeline includes PRT1419, a selective inhibitor of MCL1, PRT2527, a CDK9 inhibitor, PRT3645, a CDK4/6 inhibitor, and PRT3879, a first-in-class protein degrader.

What is the Nasdaq ticker symbol for Prelude Therapeutics?

The Nasdaq ticker symbol for Prelude Therapeutics is PRLD.